Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay

Virology

Volumn 423, Issue 2, 2012, Pages 125-133

  Chang, Kyeong Ok ^a   Takahashi, Daisuke ^a   Prakash, Om ^a   Kim, Yunjeong ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Chymostatin; Fluorescence resonance energy transfer; MD145 virus; Norwalk virus; Nuclear magnetic resonance spectroscopy; Viral proteases

Indexed keywords

CHYMOSTATIN; PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIABILITY; GENOTYPE; IC 50; MOLECULAR CLONING; MOLECULAR DOCKING; NONHUMAN; NOROVIRUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VIRUS STRAIN;

AMINO ACID SEQUENCE; DOWN-REGULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GASTROENTERITIS; GENOTYPE; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; NOROVIRUS; NORWALK VIRUS; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; SEQUENCE ALIGNMENT; VIRAL PROTEINS;

NOROVIRUS; NORWALK VIRUS;

EID: 84855787364     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.12.002     Document Type: Article

References (53)

1. Atmar R.L., Estes M.K. The epidemiologic and clinical importance of norovirus infection. Gastroenterol. Clin. North Am. 2006, 35(2):275-290. (viii).
2. Belliot G., Sosnovtsev S.V., Mitra T., Hammer C., Garfield M., Green K.Y. In vitro proteolytic processing of the MD145 norovirus ORF1 nonstructural polyprotein yields stable precursors and products similar to those detected in calicivirus-infected cells. J. Virol. 2003, 77(20):10957-10974.
3. Blanchard J.E., Elowe N.H., Huitema C., Fortin P.D., Cechetto J.D., Eltis L.D., Brown E.D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 2004, 11(10):1445-1453.
4. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 1992, 204(2):433-451.
5. C.D.C. Morbidity and Mortality Weekly Report (MMWR): Surveillance for Foodborne Disease Outbreaks - United States, 2007 2010.
6. Chen S., Chen L.L., Luo H.B., Sun T., Chen J., Ye F., Cai J.H., Shen J.K., Shen X., Jiang H.L. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. Acta Pharmacol. Sin. 2005, 26(1):99-106.
7. Coombs G.S., Rao M.S., Olson A.J., Dawson P.E., Madison E.L. Revisiting catalysis by chymotrypsin family serine proteases using peptide substrates and inhibitors with unnatural main chains. J. Biol. Chem. 1999, 274(34):24074-24079.
8. Cuerrier D., Moldoveanu T., Davies P.L. Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions. J. Biol. Chem. 2005, 280(49):40632-40641.
9. de Vries, S.J., van Dijk, M., Bonvin, A.M., 2010. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5 (5), 883-897.
10. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6(3):277-293.
11. DeLano, W.L., 2010. The PyMOL Molecular Graphics System. DeLano Scientific LLC, San Carlos, CA.
12. Dolin R. Noroviruses-challenges to control. N. Engl. J. Med. 2007, 357(11):1072-1073.
13. Dominguez C., Boelens R., Bonvin A.M. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 2003, 125(7):1731-1737.
14. Fankhauser R.L., Noel J.S., Monroe S.S., Ando T., Glass R.I. Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J. Infect. Dis. 1998, 178(6):1571-1578.
15. Ghosh A.K., Xi K., Grum-Tokars V., Xu X., Ratia K., Fu W., Houser K.V., Baker S.C., Johnson M.E., Mesecar A.D. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(21):5876-5880.
16. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. N. Engl. J. Med. 2009, 361(18):1776-1785.
17. Goddard T.D., Kneller K.D. SPARKY 3.113 2006, University of California, San Francisco.
18. Green K.Y. Caliciviruses: the noroviruses. Fields Virology 2007, 1. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
19. Green K.Y., Chanock R.M., Kapikian A.Z. Human caliciviruses. Fields Virology 2001, Vol. 1:841-874. Lippincott Williams & Wilkins, Philadelphia. 4 ed. D.M. Knipe, P.M. Howley (Eds.).
20. Grzesiek S., Bax A., Clore G.M., Gronenborn A.M., Hu J.S., Kaufman J., Palmer I., Stahl S.J., Wingfield P.T. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat. Struct. Biol. 1996, 3(4):340-345.
21. Hardy M.E., Crone T.J., Brower J.E., Ettayebi K. Substrate specificity of the Norwalk virus 3C-like proteinase. Virus Res. 2002, 89(1):29-39.
22. Hussey R.J., Coates L., Gill R.S., Erskine P.T., Coker S.F., Mitchell E., Cooper J.B., Wood S., Broadbridge R., Clarke I.N., Lambden P.R., Shoolingin-Jordan P.M. A structural study of norovirus 3C protease specificity: binding of a designed active site-directed peptide inhibitor. Biochemistry 2011, 50:240-249.
23. Inglese J., Johnson R.L., Simeonov A., Xia M., Zheng W., Austin C.P., Auld D.S. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 2007, 3(8):466-479.
24. Jaulent A.M., Fahy A.S., Knox S.R., Birtley J.R., Roque-Rosell N., Curry S., Leatherbarrow R.J. A continuous assay for foot-and-mouth disease virus 3C protease activity. Anal. Biochem. 2007, 368(2):130-137.
25. Ng K., Parra F. Calicivirus protein structures. Caliciviruses: Molecular and Cellular Virology 2010, 95-110. Caister Academic Press, Norfolk. G.S. Hansman, X.J. Jiang, K.Y. Green (Eds.).
26. Kapikian A.Z., Wyatt R.G., Dolin R., Thornhill T.S., Kalica A.R., Chanock R.M. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J. Virol. 1972, 10(5):1075-1081.
27. Kazmierski W.M., Kenakin T.P., Gudmundsson K.S. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem. Biol. Drug Des. 2006, 67(1):13-26.
28. Keller R. The Computer Aided Resonance Assignment Tutorial 2004, Verlag Goldau, Switzerland.
29. Kroneman A., Harris J., Vennema H., Duizer E., van Duynhoven Y., Gray J., Iturriza M., Bottiger B., Falkenhorst G., Johnsen C., von Bonsdorff C.H., Maunula L., Kuusi M., Pothier P., Gallay A., Schreier E., Koch J., Szucs G., Reuter G., Krisztalovics K., Lynch M., McKeown P., Foley B., Coughlan S., Ruggeri F.M., Di Bartolo I., Vainio K., Isakbaeva E., Poljsak-Prijatelj M., Grom A.H., Bosch A., Buesa J., Fauquier A.S., Hernandez-Pezzi G., Hedlund K.O., Koopmans M. Data quality of 5 years of central norovirus outbreak reporting in the European Network for food-borne viruses. J. Public Health (Oxf) 2008, 30(1):82-90.
30. Laskowski M., Kato I. Protein inhibitors of proteinases. Annu. Rev. Biochem. 1980, 49:593-626.
31. Liu B.L., Viljoen G.J., Clarke I.N., Lambden P.R. Identification of further proteolytic cleavage sites in the Southampton calicivirus polyprotein by expression of the viral protease in E. coli. J. Gen. Virol. 1999, 80(Pt. 2):291-296.
32. Nakamura K., Someya Y., Kumasaka T., Ueno G., Yamamoto M., Sato T., Takeda N., Miyamura T., Tanaka N. A norovirus protease structure provides insights into active and substrate binding site integrity. J. Virol. 2005, 79(21):13685-13693.
33. NIAID Category A, B, and C Priority Pathogens In. http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/pages/cata.aspx.
34. Nilsson M., Hedlund K.O., Thorhagen M., Larson G., Johansen K., Ekspong A., Svensson L. Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J. Virol. 2003, 77(24):13117-13124.
35. Patel M.M., Hall A.J., Vinje J., Parashara U.D. Noroviruses: a comprehensive review. J. Clin. Virol. 2009, 44(1):1-8.
36. Robert Fraczkiewicz W.B. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J. Comput. Chem. 1998, 19(3):319-333.
37. Rockx B., De Wit M., Vennema H., Vinje J., De Bruin E., Van Duynhoven Y., Koopmans M. Natural history of human calicivirus infection: a prospective cohort study. Clin. Infect. Dis. 2002, 35(3):246-253.
38. Sakai Y., Nakata S., Honma S., Tatsumi M., Numata-Kinoshita K., Chiba S. Clinical severity of Norwalk virus and Sapporo virus gastroenteritis in children in Hokkaido, Japan. Pediatr. Infect. Dis. J. 2001, 20(9):849-853.
39. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27(2):157-162.
40. Scheffler U., Rudolph W., Gebhardt J., Rohayem J. Differential cleavage of the norovirus polyprotein precursor by two active forms of the viral protease. J. Gen. Virol. 2007, 88(Pt 7):2013-2018.
41. Seah E.L., Marshall J.A., Wright P.J. Open reading frame 1 of the Norwalk-like virus Camberwell: completion of sequence and expression in mammalian cells. J. Virol. 1999, 73(12):10531-10535.
42. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274(5292):1531-1534.
43. Siebenga J.J., Vennema H., Zheng D.P., Vinje J., Lee B.E., Pang X.L., Ho E.C., Lim W., Choudekar A., Broor S., Halperin T., Rasool N.B., Hewitt J., Greening G.E., Jin M., Duan Z.J., Lucero Y., O'Ryan M., Hoehne M., Schreier E., Ratcliff R.M., White P.A., Iritani N., Reuter G., Koopmans M. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 2009, 200(5):802-812.
44. Siebenga J.J., Duizer E., Koopmans M.P.G. Norovirus epidemiology. Caliciviruses 2010, 1-24. Caister Academic Press, Norfolk. G.S. Hansman, X.J. Jians, K.Y. Green (Eds.).
45. Someya Y., Takeda N. Insights into the enzyme-substrate interaction in the norovirus 3C-like protease. J. Biochem. 2009, 146(4):509-521.
46. Someya Y., Takeda N., Wakita T. Saturation mutagenesis reveals that GLU54 of norovirus 3C-like protease is not essential for the proteolytic activity. J. Biochem. 2008, 144(6):771-780.
47. Sosnovtsev S.V., Belliot G., Chang K.O., Prikhodko V.G., Thackray L.B., Wobus C.E., Karst S.M., Virgin H.W., Green K.Y. Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. J. Virol. 2006, 80(16):7816-7831.
48. Takahashi D., Kim Y., Chang K., Anbanandam A., Prakash O. Backbone and side-chain assignments of Norwalk virus protease. Biomol. NMR Assign. 2011, Jun 8. doi:10.1007/s12104-011-9316-3.
49. Tsantrizos Y.S. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Acc. Chem. Res. 2008, 41(10):1252-1263.
50. Walker M.P., Appleby T.C., Zhong W., Lau J.Y., Hong Z. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir. Chem. Chemother. 2003, 14(1):1-21.
51. Zeitler C.E., Estes M.K., Venkataram Prasad B.V. X-ray crystallographic structure of the Norwalk virus protease at 1.5-A resolution. J. Virol. 2006, 80(10):5050-5058.
52. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4(2):67-73.
53. Zheng D.P., Widdowson M.A., Glass R.I., Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J. Clin. Microbiol. 2010, 48(1):168-177.